Clinical Scorecard: The Evolution and Effects of Thoracic Endovascular Stent-Grafting in Type B Intramural Hematoma: A Cautionary Perspective

At a Glance

Key Highlights

• Type B intramural hematoma accounts for 5% to 15% of acute aortic syndrome cases.
• Current standard of care involves optimal medical therapy with strict blood pressure control.
• TEVAR may improve aortic remodeling and reduce aortic-related death compared to medical therapy alone.
• Complications from TEVAR include retrograde aortic dissection and endoleaks.
• Patient selection for TEVAR vs. medical management is under ongoing investigation.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of type B IMH is confirmed via CT imaging.

Management

• Optimal medical therapy is the standard for uncomplicated type B IMH.
• Indications for TEVAR include persistent chest pain, increasing hematoma thickness, and hemodynamic instability.

Monitoring & Follow-up

• Serial imaging is recommended to monitor for progression of IMH.

Risks

• Patients remain at risk for late TEVAR adverse events and aortic reinterventions.

Patient & Prescribing Data

40 patients with acute uncomplicated type B IMH.

Patients with good response to OMT were discharged and followed in a dedicated aortic clinic.

Clinical Best Practices

• Maintain strict blood pressure control in patients with type B IMH.
• Monitor hematoma thickness and symptoms closely to determine need for intervention.

Related Resources & Content

• Acute Aortic Syndrome Overview
• TEVAR Outcomes in Type B IMH